BTK and B-cell chronic lymphocytic leukemia: Among these novel agents, the first-in-class Btk inhibitor ibrutinib has achieved high response rates (43–71%) in relapsed/refractory CLL, MCL and ABC-DLBCL patients, while its activity was less pronounced in FL patients (37% overall response rate) [24–27].